|
News Letter
2008
Committed
to protect Environment,
Health & Safety
An Organization Dedicated to
Prevention of Infectious Diseases and promoting public awareness
and Education about immunization and vaccine-preventable
diseases in Developing Countries
Organization:
JN is a global
research-based company that develops and markets products to
protect from Malaria, TB, HIV and Bacterial meningitis
diseases in more than 30 developing countries since 1998. Now,
JN is a leading innovation-driven Biopharmaceutical corporation.
JN stands 3rd in the
World developed
NmVac4-A/C/Y/W135™
(Meningococcal
meningitis groups A, C, Y, W-135) polysaccharide vaccine
for adults & children and
stands 2nd in the World in providing
NmVac4-A/C/Y/W135 DT™
(Meningitis A, C, Y, W-135 Diphtheria conjugate) meningococcal
vaccine for all ages.
JN
is a partner of Global Health Organization such as Clinton
Global Initiative, and GBC. JN also partnering with
several other non-profit global health organizations, NGOs,
local governments and communities in developing countries to
address the health issues related to HIV/AIDS, Malaria,
Tuberculosis and Bacterial Meningitis by
underserved communities in West Africa, South East Asia and
Latin Americas.
Research,
Development and Patenting:
JN developing vaccines for prevention and cure for
Hepatitis C, Herpes, Tuberculosis and Stroke, Epilepsy and Parkinson's disease. While research and development and clinical trials are in
its way, we filed patents to protect our intellectual properties
of our years work and investment.
Global Presence:
The Corporation opened its
first overseas branch in 2005 in Abidjan, Côte d'Ivoire and
later in 2006 in Ouagadougou, Burkina Faso. This year (2008)
first South East Asia branch opened in Malaysia. Operating in
Africa and Asia enables the company to more efficiently
distribute many of its products to resource-poor communities.
|
